Singapore, November 13, 2024 – CDW Holding Limited, a SGX Mainboard-listed company headquartered in Hong Kong, today announced significant progress in its biotechnology subsidiary’s antibody research, marking a key milestone in the Group’s diversification into the life sciences sector.
Through its subsidiaries—A Biotech Co., Limited (ABio), Tomoike Bio Limited (TBI), and GSP Enterprise Inc. (GSP)—CDW is advancing innovative antibody therapies with high potential for addressing major disease markets. ABio has achieved notable improvements in antibody affinity, specifically targeting certain cancers, by engineering the complementarity determining region (CDR3) sequences. This breakthrough enhances the antibodies’ ability to bind to cancer-related antigens, increasing their therapeutic potential.
The Group aims to complete efficacy tests in mice by the end of 2025 and to finalize a comprehensive antibody library by the same year. This library, developed using advanced phage display technology, is expected to contain up to 10111011 to 10121012 unique antibody gene sequences—a scale comparable to the natural antibody repertoire produced by a human in a lifetime. Once operational, the library will support both internal research and contract services for universities and research institutions.
The global antibody therapy market, valued at US$214.7 billion in 2022, is projected to reach US$638.2 billion by 2032. Similarly, the oncology market is forecast to grow from more than US$280 billion in 2022 to US$690 billion by 2032. CDW’s entry into this space positions the Group to capitalize on these rapidly expanding markets.
Mr. KATO Tomonori, Chairman and Chief Executive Officer of CDW Holding Limited, stated: “We are pleased to see ABio and GSP making great progress in the development of their antibody technologies. We believe that our Biotech business is on the right path for strong future growth to help in our business diversification, and I look forward to further progress in this area.”
————
CDW Holding Limited (the “Company” and together with its subsidiaries, the “Group”) is a Japanese-managed precision components specialist serving the global market focusing on the production and supply of niche precision components for digital instrument panels in the automobile industry, notebook computers, consumer and information technology equipment, office equipment and electrical appliances, and an original equipment manufacturer. The Group is headquartered in Hong Kong and has operations in Japan, China, South Korea, Thailand and the Philippines. The Company has been identifying new businesses to invest in with the potential for growth and entered as part of its diversification strategy and has made forays into the Life Sciences sector since 2016. The Company’s aim for its Life Sciences business is to identify research-driven yet commercialisable projects that can have a positive impact on the quality of human life.
